Laboratoires Servier
Tracked across 6 events · 45 articles · First seen Apr 10, 2026 · Last active Sep 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Laboratoires Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics, which will enhance its position in neuromuscular disorders and support its 2030 ambition in neurology.
Jun 01, 2026 · 6 articles
Business
Impact: Laboratoires Servier is strengthening its commitment to rare neurological diseases and advancing its 2030 ambition by partnering with Foundation to develop innovative treatments.
Jun 10, 2026 · 9 articles
Business
Impact: Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Jul 20, 2026 · 6 articles
Business
Impact: Commercial product OJEMDA included in acquired portfolio.
Jul 14, 2026 · 6 articles
Tech
Insilico Medicine announced on September 9-10, 2026 that it has dosed the first patient with Rentosertib (ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), at United Medical College…
Impact: Laboratoires Servier is listed as a collaboration partner of Insilico Medicine, supporting its commercial model. The event has minimal direct impact on Laboratoires Servier.
Sep 10, 2026 · 6 articles
Business
Impact: Laboratoires Servier is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Sep 04, 2026 · 12 articles
ERGEN INTELLIGENCE
Track Laboratoires Servier live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard